IL-12 Killer Engager Molecules for NK Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer treatment face challenges in effectively activating and sustaining Natural Killer (NK) cell activity, particularly in inducing degranulation, IFNγ secretion, and overcoming NK cell exhaustion, which are crucial for targeted cancer cell killing.
Innovation Solution
Development of multispecific Killer Engager compounds incorporating an IL-12-based NK activating domain, an NK engaging domain, and a targeting domain, which selectively bind to NK cells and tumor antigens, enhancing NK cell-mediated cytotoxicity and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cancer, then general cancer treatment is provided, but NK cell activation and sustained activity are insufficient
Solution Approach 1:
The therapy is segmented into three distinct functional domains within a single molecule: (1) targeting domain that binds to tumor antigens, (2) NK cell engaging domain that binds to NK cell receptors (CD16, CD3, or FcγRIII), and (3) IL-12 activating domain that provides cytokine stimulation. This segmentation allows each domain to independently perform its specific function while working synergistically to overcome the limitations of current therapies.
Solution Approach 2:
The patent merges multiple therapeutic functions into a single multispecific Killer Engager molecule. By combining tumor targeting, NK cell engagement, and IL-12 activation in one molecular construct, the therapy achieves coordinated action that enhances reliability of NK cell activation while improving cancer cell killing efficiency compared to separate therapies.
2Productivity
If NK cell activity is enhanced through activation, then cancer cell killing is improved, but NK cell exhaustion occurs
Solution Approach 1:
The IL-12 activating domain provides continuous cytokine stimulation to NK cells throughout the engagement process. This continuous activation signal prevents NK cell exhaustion by maintaining sustained NK cell activity and functional capacity over extended periods, allowing prolonged cancer cell killing without loss of efficacy.
Solution Approach 2:
IL-12 acts as an intermediary cytokine that mediates between the NK cell engaging domain and the NK cell itself. The IL-12 domain translates the physical engagement event into sustained biochemical activation signals within the NK cell, preventing exhaustion by providing ongoing metabolic and functional support.
3Productivity
If multispecific Killer Engager compounds are developed, then NK cell-mediated cytotoxicity is enhanced, but molecular complexity increases
Solution Approach 1:
The multispecific Killer Engager molecule is designed with universal functionality where a single molecular platform can target different tumor antigens by simply changing the targeting domain, while maintaining the same NK cell engaging domain and IL-12 activating domain. This multi-functionality reduces the need to develop entirely new complex molecules for different cancer types.
Solution Approach 2:
Different domains of the molecule have specialized local functions: the targeting domain handles antigen recognition, the NK cell engaging domain handles immune cell binding, and the IL-12 activating domain handles cytokine stimulation. This division of labor into specialized local regions allows the complex molecule to be designed and optimized systematically rather than as an undifferentiated complex structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-12-based Killer Engager compounds induce robust NK cell degranulation, IFNγ secretion, and rescue NK cell exhaustion, demonstrating enhanced cancer cell killing capabilities and immune activation.
Implementation Method 1
The NK activating domain generally includes an IL-12-based polypeptide
Implementation Method 2
an NK cell engaging domain that selectively binds to an NK cell
Implementation Method 3
a targeting domain that specifically binds to a target antigen
Implementation Method 4
induce NK-mediated killing of a cancer cell
Data Source
AI summary
A compound generally includes an NK cell engaging domain operably linked to the NK cell engaging domain. The NK activating domain generally includes an IL-12-based polypeptide. The NK engaging domain selectively binds to an NK cell and an NK activating domain. In some embodiments, the IL-12 polypeptide can include an IL-12A polypeptide, an IL-12B polypeptide, or both an IL-12A polypeptide and an IL-12B polypeptide. In some embodiments, the NK activating domain includes an IL-12A polypeptide, an IL-12B polypeptide, and a flanking sequence linking the IL-12A polypeptide and the IL-12B polypeptide. In some embodiments, the compound can include a second NK activating domain. In some embodiments, the compound can include ones or more targeting domains.